Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART
Integrase inhibitors do not raise risk of IRIS in severely immunocompromised people
Average time from HIV diagnosis to treatment fell to six days in 2016 in San Francisco
Same-day treatment start improves retention in care and viral suppression in Lesotho
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason
Dolutegravir and lamivudine potent and safe in people starting HIV therapy for the first time
Baseline CD4 count biggest factor in long-term immune system improvements after starting HIV therapy
HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa
HIV diagnoses in English gay men have been falling since 2014
